HC Wainwright reissued their buy rating on shares of Immix Biopharma (NASDAQ:IMMX – Free Report) in a research note published on Monday morning, Benzinga reports. They currently have a $7.00 price objective on the stock. HC Wainwright also issued estimates for Immix Biopharma’s Q3 2024 earnings at ($0.16) EPS, Q4 2024 earnings at ($0.17) EPS, FY2024 earnings at ($0.67) EPS, Q1 2025 earnings at ($0.13) EPS, Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.52) EPS.
Immix Biopharma Stock Performance
Shares of IMMX opened at $2.28 on Monday. Immix Biopharma has a 1 year low of $1.75 and a 1 year high of $7.75. The firm has a fifty day moving average of $2.10 and a 200-day moving average of $2.47. The company has a market cap of $60.22 million, a price-to-earnings ratio of -2.45 and a beta of 0.17.
Immix Biopharma (NASDAQ:IMMX – Get Free Report) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.06. Analysts predict that Immix Biopharma will post -0.88 EPS for the current year.
Institutional Inflows and Outflows
About Immix Biopharma
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
Recommended Stories
- Five stocks we like better than Immix Biopharma
- How to Calculate Stock Profit
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- Stock Analyst Ratings and Canadian Analyst Ratings
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- 3 Monster Growth Stocks to Buy Now
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.